Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer, July 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 234 articles:
HTML format


 

Single Articles

  1. PICCOLINI A, Paciotti M, Korn SM, Qian Z, et al
    Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).
    Clin Genitourin Cancer. 2026 Jun 5:102595. doi: 10.1016/j.clgc.2026.102595.
    PubMed    
    Abstract available

  2. AL-ASFORY K, Mortada WI, El-Khawaga OY, Magar RW, et al
    Mentha-derived green synthesized ZnO nanoparticles potentiate methotrexate induced molecular and migratory inhibition via gene expression modulation in T24 bladder cancer cells.
    Nanomedicine. 2026 Jul 3:102991. doi: 10.1016/j.nano.2026.102991.
    PubMed    
    Abstract available

  3. CHEN N, Chen L, Cai J, Tan M, et al
    Extraperitoneal Single-Port Robotic-Assisted Radical Cystectomy with Orthotopic Ne-obladder: Technique and Surgical Considerations.
    Int Braz J Urol. 2027;53:e20260422.
    PubMed    
    Abstract available

  4. BIDEGAIN GARBALA E, Arteaga Mazuelas M, Jarne Betran V, Abinzano Guillen ML, et al
    [Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].
    An Sist Sanit Navar. 2026;49:e1145.
    PubMed    
    Abstract available

  5. YE Z, Cui W, Theodorescu D, Finkelstein J, et al
    Estimating Mosaic Loss of the Y Chromosome in Male Bladder Cancer Participants Using "All of Us" Data.
    Stud Health Technol Inform. 2026;338:443-447.
    PubMed    
    Abstract available

  6. LAO J, Yuan X, Liang S, Deng K, et al
    Targeted Delivery of Indole-3-Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8(+) T Cell-Mediated Immunotherapy Response in Bladder Cancer.
    Adv Sci (Weinh). 2026 Jul 2:e76319. doi: 10.1002/advs.76319.
    PubMed    
    Abstract available

  7. XIE P, Wang Y, Lu L, Chen J, et al
    HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.
    Cancer Metastasis Rev. 2026;45:44.
    PubMed    
    Abstract available

  8. MOMENAH MA, Al-Qahtani WS
    An exploratory study of BLCA-4 expression, STR analysis, and urothelial cytology in smokers versus non-smokers with bladder cancer.
    Front Oncol. 2026;16:1851761.
    PubMed    
    Abstract available

  9. ZHANG X, Xin P, Du Y, Wang R, et al
    Biomimetic delivery of a STING agonist via tumor antigen-primed dendritic cell membrane nanovesicles for bladder cancer immunotherapy.
    Mater Today Bio. 2026;39:103333.
    PubMed    
    Abstract available

  10. GUO E, Chen L, Li Y, Fan P, et al
    A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.
    J Magn Reson Imaging. 2026 Jul 2. doi: 10.1002/jmri.70401.
    PubMed    
    Abstract available

  11. CHEN Z, Wang S, Sun Z, Liao H, et al
    An AI-Driven Multi-Omics Framework Identifies CASP8 as a Clinically Actionable Pyroptosis Biomarker in Bladder Cancer.
    Biofactors. 2026;52:e70130.
    PubMed    
    Abstract available

  12. RODRIGUEZ-PARRAS P, Angel Arrabal-Polo M, Arrabal-Martin M
    Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.
    Clin Genitourin Cancer. 2026;24:102596.
    PubMed    
    Abstract available

  13. KOHLI M, Goel S, Iqbal A, Aggarwal A, et al
    Impact of 18-FDG PET-CT on the preoperative staging and management of Incidental Gall Bladder Cancer (IGBC)- A prospective study from a tertiary care centre in North India.
    Eur J Surg Oncol. 2026;52:111982.
    PubMed    
    Abstract available

  14. ODAGIRI K, Tasaki Y, Naiki T, Morikawa T, et al
    Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.
    Cancer Med. 2026;15:e72072.
    PubMed    
    Abstract available

  15. BULUT AS, Kizilkan Y
    Evaluation and comparison of voided urine and bladder washing cytologies according to the Paris system.
    Rev Assoc Med Bras (1992). 2026;72:e20251936.
    PubMed    
    Abstract available

  16. NOVIARDI DEPP, Seputra KP, Daryanto B, Dhani FK, et al
    Atypical urothelial cells investigation with automated urinalysis and expert review of microscopic sediment as early parameter for suspected bladder cancer patients.
    Arch Ital Urol Androl. 2026;98:15595.
    PubMed    
    Abstract available

  17. QIU H, Du H, Li X, Wang X, et al
    Urinary tract infection caused by rare yeast Vanrija humicola in a urothelial carcinoma patient: a case report and literature review.
    Front Immunol. 2026;17:1845780.
    PubMed    
    Abstract available

  18. NOHMI RL, Marques FC, Brito HC, Leite LM, et al
    Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Adv Radiat Oncol. 2026;11:102075.
    PubMed    
    Abstract available

  19. SHIRAISHI Y, Furubayashi N, Tsujita J, Takayama A, et al
    Ureteral Orifice Stricture After Transurethral Resection of Bladder Tumors Involving the Ureteral Orifice or Adjacent Area: Clinical Course and Outcomes.
    In Vivo. 2026;40:2327-2334.
    PubMed    
    Abstract available

  20. KUO YC, Wang HY, Liao TL, Weng YS, et al
    A miR-124-3p/PKC-delta Regulatory Axis Restrains Bladder Cancer Growth and Malignant Progression.
    In Vivo. 2026;40:1992-2002.
    PubMed    
    Abstract available

  21. ATIA N, Osman Y, Abdel-Aziz AF, Refaat S, et al
    Angiotensin Converting Enzyme (ACE) insertion/deletion (rs1799752) gene polymorphism and bladder cancer aggressiveness in Egyptian patients: A pilot case-control study.
    Mol Biol Rep. 2026;53:1058.
    PubMed    
    Abstract available

  22. ANING J, Catto JWF, Martin R, Chatterton K, et al
    State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).
    BJUI Compass. 2026;7:e70236.
    PubMed    
    Abstract available

  23. OZCAN L, Boylu A, Polat EC, Culha MG, et al
    Is the albumin/globulin ratio a predictor of response to neoadjuvant chemotherapy before cystectomy for muscle-invasive bladder cancer?
    Cent European J Urol. 2026;79:103-110.
    PubMed    
    Abstract available

  24. GAMBINA K, Tymm C, Paiola M, Tanji K, et al
    Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma.
    Front Immunol. 2026;17:1793351.
    PubMed    
    Abstract available

  25. ZHANG G, Hou J, Guo M, JiamingYan, et al
    Integrating whole-genome bisulfite sequencing and TCGA data reveals methylation patterns associated with the MTHFR 677 C > T Variant.
    Sci Rep. 2026;16:19756.
    PubMed    
    Abstract available

  26. CONTIERI R, Hurle R
    Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective H
    Eur Urol Oncol. 2026 Jun 29:S2588-9311(26)00181.
    PubMed    


  27. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.
    Cancer Genomics Proteomics. 2026;23:777-805.
    PubMed    
    Abstract available

  28. PILALA KM, Papadimitriou AM, Papadimitriou MA, Panoutsopoulou K, et al
    Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.
    J Biol Chem. 2026 Jun 29:113302. doi: 10.1016/j.jbc.2026.113302.
    PubMed    
    Abstract available

  29. ZHANG P, Wu JC, Wang H, You HH, et al
    In-situ cascade assembled peptide-drug conjugate for the treatment of bladder cancer by enhancing membrane-entry and lysosome destabilization.
    Biomaterials. 2026;335:124405.
    PubMed    
    Abstract available

  30. MAHAPATRA S, Humble RM, Cordeiro-Rudnisky F, Hafez KS, et al
    Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.
    Am J Clin Pathol. 2026;165:aqag072.
    PubMed    
    Abstract available

  31. ZHANG J, Wu B, Xie C, Qian X, et al
    Treatment-Related Cystitis During Intravesical Chemotherapy: Incidence, Risk Factors, And Nursing-Pathway Associations.
    J Vis Exp. 2026;.
    PubMed    
    Abstract available

  32. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.
    Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20051.
    PubMed    


  33. LIU H, Chu Y, Hou J, Wang Y, et al
    Targeting macrophage-associated core genes for prognostic prediction and therapeutic insights in bladder cancer.
    Discov Oncol. 2026 Jun 27. doi: 10.1007/s12672-026-05338.
    PubMed    
    Abstract available

  34. ZHAO Z, Liu X, Zhong Q, Liu L, et al
    Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis.
    Front Oncol. 2026;16:1819312.
    PubMed    
    Abstract available

  35. LEITSMANN C, Reese AS, Zigeuner R, Zurl H, et al
    Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?
    Front Surg. 2026;13:1813017.
    PubMed    
    Abstract available

  36. GHOREIFI A, Dudinec JV, Refugia JM, Zahir M, et al
    Complete pathological response in patients with bladder cancer: predictors and outcomes.
    Ther Adv Urol. 2026;18:17562872261458110.
    PubMed    
    Abstract available

  37. XIAO X, Jia X, Shen R, Song D, et al
    Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.
    iScience. 2026;29:116353.
    PubMed    
    Abstract available

  38. JANG A, Grier AL, Sheng IY, Bari S, et al
    Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.
    Drugs Context. 2026;15:2025-9-1.
    PubMed    
    Abstract available

  39. MAHMUD S, Dwyer Orr L, Cline M, Mirsalehi A, et al
    Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.
    Oncologist. 2026 Jun 27:oyag243. doi: 10.1093.
    PubMed    
    Abstract available

  40. CHANG Y
    Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
    Eur Urol Oncol. 2026 Jun 28:S2588-9311(26)00169.
    PubMed    


  41. ERICHSEN DW, Kyro C, Schullehner J, Rosthoj S, et al
    Source-specific nitrate and nitrite intake and bladder cancer: findings from the Danish Diet, Cancer and Health Cohort.
    Environ Int. 2026;214:110387.
    PubMed    
    Abstract available

  42. HEKMATIRAD S, Gholizadeh F, Montazeri S, Sharifi L, et al
    Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer.
    Sci Rep. 2026 Jun 27. doi: 10.1038/s41598-026-59564.
    PubMed    
    Abstract available

  43. Z KHAN M, Atta MA, Kotb A, Ismail A, et al
    Beyond the Rotisserie: Dispelling the Myths of Intravesical Therapy and Pioneering a Precision Future for Bladder Cancer.
    Urol Res Pract. 2026;52:1-8.
    PubMed    
    Abstract available

  44. SAYEGH Y, McNutt B, Le MK, Liao IC, et al
    Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance.
    Cancer Cytopathol. 2026;134:e70117.
    PubMed    
    Abstract available

  45. STECKENRIDER H, Delgado J, Ritch C
    Surveillance Protocols: Balancing Patient Burden and Cancer Control.
    Urol Clin North Am. 2026;53:453-461.
    PubMed    
    Abstract available

  46. TAZEGUL TE, O'Donnell M, Hougen HY
    Bacillus Calmette-Guerin Therapy: Optimizing Outcomes amid Challenges.
    Urol Clin North Am. 2026;53:413-427.
    PubMed    
    Abstract available

  47. FILON M, Kabra S, Smelser W, Schmidt B, et al
    Transurethral Resection of Bladder Tumors: Evolving Standards of Care-Optimizing Resection, Staging Accuracy, and Recurrence Reduction.
    Urol Clin North Am. 2026;53:365-376.
    PubMed    
    Abstract available

  48. MOUSA MK, Carvalho LB, Giddey AD, Figueiredo A, et al
    Evaluation of FASP for Mass Spectrometry-Based Untargeted Metabolomics Analysis of Urine Samples.
    J Proteome Res. 2026;25:3769-3777.
    PubMed    
    Abstract available

  49. JIANG Y, Xue Y, Chen C, Fang T, et al
    Self-Supervised Denoising Network for Quantitative Stimulated Raman Scattering Microscopy in Cross-Type Samples.
    Anal Chem. 2026;98:18596-18606.
    PubMed    
    Abstract available

  50. KACAN T, Tezcan B, Yildiz AK, Gokkurt Y, et al
    Impact of spinal versus general anesthesia on dwell time of early immediate intravesical epirubicin administration following transurethral resection of bladder tumor: an observational study.
    World J Urol. 2026;44:325.
    PubMed    
    Abstract available

  51. SUN RM, Yang Y, Lai YD, Wang HN, et al
    BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.
    J Exp Clin Cancer Res. 2026;45:134.
    PubMed    
    Abstract available

  52. SANO T, Ikeda J, Yoshida T, Nakamoto T, et al
    Hydronephrosis modifies the association between ureteroscopy and intravesical recurrence risk after radical nephroureterectomy for upper tract urothelial carcinoma.
    Sci Rep. 2026;16:18820.
    PubMed    
    Abstract available

  53. PU C, Lv Z, Chen G
    A systematic review and meta-analysis: evaluating the enhanced recovery after surgery protocol for perioperative care in robot-assisted radical cystectomy.
    J Robot Surg. 2026;20:449.
    PubMed    
    Abstract available

  54. CRETTENAND F, Papagiannakis A, Stritt K, Grillo N, et al
    Impact of continuous local anesthetic wound infiltration on postoperative outcomes following open radical cystectomy: a comprehensive evaluation.
    World J Urol. 2026;44:315.
    PubMed    
    Abstract available

  55. RAM P, Merseburger AS, Huabkong M, Tohi Y, et al
    Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma.
    World J Urol. 2026;44:307.
    PubMed    
    Abstract available

  56. WATANABE R, Koshitani T, Hashidume S, Kasho K, et al
    Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation.
    Clin J Gastroenterol. 2026;19:684-689.
    PubMed    
    Abstract available

  57. HALIS A, Celiker D
    Evaluation of large language models for VI-RADS reports: a comparative analysis of zero-shot and few-shot prompting.
    BMC Med Imaging. 2026;26:265.
    PubMed    
    Abstract available

  58. LU X, You X, Liu T, Wei Y, et al
    The gene mutation pattern of urachal squamous cell carcinoma resembles that of gastrointestinal tumors: a rare case with favorable prognosis following surgery and adjuvant chemotherapy.
    World J Surg Oncol. 2026;24:224.
    PubMed    
    Abstract available

  59. CREFFIER CWG, Chemasle C
    Learning Curve and Surgeon Experience in En Bloc Transurethral Resection of Bladder Tumour: A Retrospective Cohort Study.
    ANZ J Surg. 2026;96:1528-1535.
    PubMed    
    Abstract available

  60. KITNITCHEE M, Sirivisoot S, Siripoonsub J, Chimnakboon N, et al
    BRAF(V595E) detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma.
    Vet Res Commun. 2026;50:245.
    PubMed    
    Abstract available

  61. HUNT KS, Cooke S, Kuehm LM, Lobb TA, et al
    Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.
    Cancer Immunol Res. 2026;14:1068-1079.
    PubMed    
    Abstract available

  62. FANG C, Dai J, Weng Z, Zhang L, et al
    A machine learning-based epigenetic signature reveals YTHDC1 stabilizes POU5F1 to oppose tumor progression.
    J Transl Med. 2026;24:608.
    PubMed    
    Abstract available

  63. ALHAMDANI Z, Obrecht F, Sethi K, Bolton D, et al
    The modified G8 screening tool to predict post-operative complications and survival after robot-assisted radical cystectomy - a pilot study.
    BMC Urol. 2026;26:104.
    PubMed    
    Abstract available

  64. KOSHIBA T, Hakamata M, Tomita Y, Yamagishi I, et al
    Aortoesophageal fistula caused by Mycobacterium bovis following intravesical Bacillus Calmette-Guerin therapy: a case report and literature review.
    BMC Infect Dis. 2026;26:813.
    PubMed    
    Abstract available

  65. ZHOU Q, Bao G, Liu M, Gong L, et al
    Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.
    BMC Urol. 2026;26:95.
    PubMed    
    Abstract available

  66. LIU Y, Song Y, Qi N, Han C, et al
    Immediate Vs. Delayed single post-operative intravesical instillation of chemotherapy in reducing bladder recurrence rate in upper tract urothelial carcinoma patients after radical nephroureterectomy.
    World J Urol. 2026;44:226.
    PubMed    
    Abstract available

  67. ZHANG J, Su S, Liu M, Luo Y, et al
    Nanoparticles co-loaded with bacillus Calmette-Guerin pure protein derivative and doxorubicin for bladder tumor therapy.
    BMC Biotechnol. 2026;26:39.
    PubMed    
    Abstract available

  68. MASTROIANNI R, Ragusa A, Iannuzzi A, Tuderti G, et al
    Impact of transvaginal extraction on continence after robotic cystectomy with orthotopic neobladder.
    World J Urol. 2026;44:197.
    PubMed    
    Abstract available

  69. LI Z, Yan R, Zhao K, Xiao X, et al
    Global trends in robot-assisted radical cystectomy: a bibliometric and visualization analysis.
    J Robot Surg. 2026;20:245.
    PubMed    
    Abstract available

  70. XIN S, Li G, Zhao L, Su J, et al
    The BCAA metabolism-related gene BCAT1 promotes the progression of bladder urothelial carcinoma through the PI3K/AKT/mTOR signalling pathway.
    Funct Integr Genomics. 2026;26:39.
    PubMed    
    Abstract available

  71. GASPARINI A, Crowther MJ, Schaffer JM
    Standardized survival probabilities and contrasts between hierarchical units in multilevel survival models.
    BMC Med Res Methodol. 2026;26:45.
    PubMed    
    Abstract available

  72. LIANG P, Chen J, Shen J, Wang Y, et al
    Transurethral thulium laser resection via ureterorenoscope for pediatric low-grade urothelial carcinoma of the bladder: a case report.
    BMC Surg. 2026;26:172.
    PubMed    
    Abstract available

  73. AKARKEN I, Tarhan H, Karaoz F, Deliktas H, et al
    Clinical Features and Treatment Outcomes of Large Bladder Tumors Nearly Filling the Bladder.
    Urol J. 2026;23:48-53.
    PubMed    
    Abstract available

  74. FAYYAZ S, Sauer UG, Li Q, Guthmann H, et al
    Reassessing the carcinogenic potential of dibutyl hydrogen phosphate: new insight from repeated-dose toxicity studies.
    Arch Toxicol. 2026;100:2111-2134.
    PubMed    
    Abstract available

  75. RAN M, Chen X, Xiao G, Huang R, et al
    Exploration of neutrophil-associated genes in the prognosis of bladder urothelial carcinoma based on a machine learning and multi-omics data integration framework.
    Hum Genomics. 2026;20:37.
    PubMed    
    Abstract available

  76. OZDEN SB, Kalayci A, Gurses I, Ozdemir F, et al
    Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping.
    BMC Urol. 2026;26:41.
    PubMed    
    Abstract available

  77. GUO Z, Wang G
    Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report.
    BMC Urol. 2026;26:33.
    PubMed    
    Abstract available

  78. GUNER E, Sam E, Fakir AE, Guneren MS, et al
    Factors predicting ureteral stenosis after transurethral resection of the ureteral orifice: a two-center, retrospective clinical study.
    BMC Urol. 2025;26:24.
    PubMed    
    Abstract available

  79. YUAN S, Yang K, Wu H, Peng L, et al
    Diagnostic performance of artificial intelligence in detecting bladder carcinoma.
    World J Urol. 2025;44:63.
    PubMed    
    Abstract available

  80. AVELINO ALN, Goncalves FD, Ferreira JNM, Vasconcelos GR, et al
    Investigation of androgen receptor expression in urothelial carcinoma of the bladder.
    BMC Urol. 2025;25:308.
    PubMed    
    Abstract available

  81. LIU J, Allen RC, Stephens JT Jr, Huang H, et al
    Selective Tumor Cytotoxicity via Singlet Oxygen: Investigating Eosinophil Peroxidase and Myeloperoxidase in Cancer Therapy.
    Oncology. 2026;104:849-862.
    PubMed    
    Abstract available

  82. MANGOLD MH, Wieland VLS, Grilli M, Studier-Fischer A, et al
    Tranexamic acid in radical cystectomy: a systematic review and meta-analysis of efficacy and safety.
    World J Urol. 2025;43:560.
    PubMed    
    Abstract available

  83. IMURA S, Ogi Y, Ishimaru K, Koga S, et al
    Small Intestinal Adhesion at a Parastomal Hernia of the Ileal Conduit and Hernia Repair with Laparoscopy and Tailored Mesh: A Case Report.
    J Nippon Med Sch. 2026;93:279-283.
    PubMed    
    Abstract available

  84. MOYER JA, Ashraf M, Mi L, Zganjar AJ, et al
    Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 9:S1078-1439(26)00568-5. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available

  85. STROJNY Z, Kanikowska D, Kanikowska A, Tomczak Z, et al
    The significance of vascular endothelial growth factor and systemic inflammatory reaction in bladder cancer patients.
    Cytokine. 2026;205:157190.
    PubMed    
    Abstract available

  86. DI LORENZO G
    Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Oncology. 2026 Jul 9:1-7. doi: 10.1159/000553466.
    PubMed    


  87. CHEN N, Cai J, Feng J, He Y, et al
    A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045.
    Sci Prog. 2026;109:368504261466968.
    PubMed    
    Abstract available

  88. ZHANG X, Ge P, Chen Q, Wang S, et al
    Liquid-liquid phase separation-associated gene networks link EMT and ferroptosis to define a PDGFRB-centered prognostic signature in bladder cancer.
    Front Immunol. 2026;17:1846096.
    PubMed    
    Abstract available

  89. BARTH G, Koch S, Ecke TH
    Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.
    Cancer Cytopathol. 2026;134:e70130.
    PubMed    
    Abstract available

  90. GUAN J, Jiang X, Lv Y, Xue Y, et al
    Visualizing NO(2)(-)/NAD(P)H metabolic crosstalk in E. coli-infected bladder cancer via a dual-responsive probe.
    Chem Commun (Camb). 2026 Jul 9. doi: 10.1039/d6cc02834.
    PubMed    
    Abstract available

  91. THIBAULT C, Blons H, Allory Y, Harba A, et al
    Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
    Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00182-3. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available

  92. GREIDANUS J, van Dijk-de Haan MC, Messina A, Calareso G, et al
    MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.
    Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00154-9. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available

  93. ZHESTKOV I A, Kamalov D M, Oleynikova N A, Nesterova O Y, et al
    [Tumor-associated fibroblasts and clinical and morphological features of bladder cancer].
    Urologiia. 2025;:90-94.
    PubMed    
    Abstract available

  94. PETERSEN E, Sheldon J, Torgerson H, Kirschenbaum M, et al
    The impact of cachexia and sarcopenia in bladder cancer.
    Curr Opin Support Palliat Care. 2026 Jul 9. doi: 10.1097/SPC.0000000000000811.
    PubMed    
    Abstract available

  95. PAN CX, Mossanen M, Ellis JL, Ma AH, et al
    Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.
    Nanomedicine (Lond). 2026 Jul 8:1-7. doi: 10.1080/17435889.2026.2693194.
    PubMed    
    Abstract available

  96. LI A, Tang C, Wei X, Liu F, et al
    Endourological autologous bypass-ureteroplasty for anastomotic atresia in orthotopic neobladder: a novel surgical approach and case report.
    Can J Urol. 2026;33:643-648.
    PubMed    
    Abstract available

  97. XU H, Yang C, Fu Q, Zeng S, et al
    Hypoxia-induced exosomal LNCOC1 orchestrates bladder cancer progression via the YBX1/PIK3CA axis and serves as a potential liquid biopsy biomarker.
    Cell Oncol (Dordr). 2026 Jul 7. doi: 10.1007/s13402-026-01257.
    PubMed    
    Abstract available

  98. YU L, Liu T, Cai Y, Gai Y, et al
    An Interface-Regulated Electrochemical Biosensing Platform Based on the Cascade Amplification of Primer Exchange Reaction and CRISPR/Cas12a for Noninvasive Bladder Cancer Diagnosis.
    Anal Chem. 2026 Jul 7. doi: 10.1021/acs.analchem.6c02591.
    PubMed    
    Abstract available

  99. SU YL, Huang SY, Kuo CW, Xiao LY, et al
    Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
    J Immunother Cancer. 2026;14:e014770.
    PubMed    
    Abstract available

  100. XIANG L, Li Y, Dong X, Yan Y, et al
    EIF4A3 facilitates METTL3-mediated m(6)A methylation of circPCMTD1 to drive bladder cancer progression via miR-3681-5p/HPSE axis.
    Cell Signal. 2026 Jul 7:112725. doi: 10.1016/j.cellsig.2026.112725.
    PubMed    
    Abstract available

  101. MONSONIS USO R, Ponce Blasco P, Canos Nebot A, Barrios Arnau L, et al
    Association Between Perioperative Blood Transfusion and Survival Outcomes After Radical Cystectomy for Bladder Cancer.
    Actas Urol Esp (Engl Ed). 2026 Jul 7:502001. doi: 10.1016/j.acuroe.2026.502001.
    PubMed    
    Abstract available

  102. SIM KC, Sung DJ, Han NY, Han YE, et al
    Correlation Between the Natural Course and Magnetic Resonance Imaging Features of Bacillus Calmette-Guerin-Related Granulomatous Prostatitis in Patients With Bladder Cancer.
    J Korean Med Sci. 2026;41:e178.
    PubMed    
    Abstract available

  103. OTO J, Herreros-Pomares A, Verger P, Herranz R, et al
    A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.
    J Transl Med. 2026 Jul 6. doi: 10.1186/s12967-026-08570.
    PubMed    
    Abstract available

  104. LIU W, Gong B, Zhang G, Guo Y, et al
    Development of multiphasic CT-based delta-radiomics model for predicting postoperative recurrence risk in bladder cancer.
    BMC Med Imaging. 2026 Jul 7. doi: 10.1186/s12880-026-02554.
    PubMed    
    Abstract available

  105. YIM W, Kang H, Kang BH, McGinnis ME, et al
    Publisher Correction: Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
    Nat Nanotechnol. 2026 Jul 6. doi: 10.1038/s41565-026-02239.
    PubMed    


  106. LI Z, Fu Y, Zhang J, Wang Y, et al
    Challenges in postoperative self-management for patients with bladder cancer and urinary stoma: a qualitative study.
    Support Care Cancer. 2026;34:740.
    PubMed    
    Abstract available

  107. PETRELLI F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al
    Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.
    Curr Oncol Rep. 2026;28:72.
    PubMed    
    Abstract available

  108. ZOU XC, Yu ZJ, Yuan YY, Chao HC, et al
    Interpretable machine learning model of contrast-enhanced CT radiomics for predicting post-BCG recurrence in high-grade non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:486.
    PubMed    
    Abstract available

  109. SCHERPING AK, Tomasik B, Luzha J, Schostak M, et al
    Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.
    Virchows Arch. 2026 Jul 6. doi: 10.1007/s00428-026-04639.
    PubMed    
    Abstract available

  110. MARRONE MT, Bagley E, Butler KR, Couper DJ, et al
    Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.
    Cancer Prev Res (Phila). 2026 Jul 6. doi: 10.1158/1940-6207.CAPR-25-0499.
    PubMed    
    Abstract available

  111. WANG T, Liao X, Zhang J, Xu X, et al
    Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.
    Cancer Sci. 2026 Jul 6. doi: 10.1111/cas.70455.
    PubMed    
    Abstract available

  112. MUGLIA VF, Reis RB
    Editorial for "A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels".
    J Magn Reson Imaging. 2026 Jul 6. doi: 10.1002/jmri.70416.
    PubMed    


  113. FAKHOURI F, Candido P, Pimenta R, Guimaraes VR, et al
    The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells.
    BMC Urol. 2026 Jul 4. doi: 10.1186/s12894-026-02241.
    PubMed    
    Abstract available

  114. YANG L, Zhang JM, Chen YJ, Wei ZQ, et al
    Multi-omics profiling identifies CDK1 as a key mediator of mitosis through the PTN pathway in bladder cancer.
    Future Sci OA. 2026;12:2696931.
    PubMed    
    Abstract available

  115. MOUSA MK, Soares NC, Santos HM
    LC-MS-Based Metabolomics and Proteomics Sample Preparation of Urine: Methods and Multi-Omics Integration.
    Adv Exp Med Biol. 2026;1510:1-20.
    PubMed    
    Abstract available

  116. CHEN Y, Zhuang J, Yu H, Li K, et al
    Hypoxia remodels circSTX6 nuclear export through URH49-ALYREF to drive IGF1-mediated bladder cancer progression.
    Cell Signal. 2026;147:112723.
    PubMed    
    Abstract available

  117. DOHERTY R, Kiadaliri A, Hajizadeh M
    Socioeconomic inequalities in bladder cancer mortality in Canada: Temporal trends over three decades, 1990-2019.
    Public Health. 2026;258:106396.
    PubMed    
    Abstract available

  118. SHIRANI F, Lashay A
    Cutaneous ureterostomy versus ileal conduit as urinary diversion in patients with muscle-invasive bladder cancer undergoing radical cystectomy: A comparative analysis of high-risk cases.
    Urologia. 2026 Jul 4:3915603261461658. doi: 10.1177/03915603261461658.
    PubMed    
    Abstract available

  119. WANG ZQ, Song Q, Liu JY, Peng CY, et al
    A Solid-State Near-Infrared Fluorescent Probe by a Synergistic Extended Conjugated System for Detecting Cys with Long-Term Imaging in Orthotopic Bladder Cancer.
    Anal Chem. 2026 Jul 4. doi: 10.1021/acs.analchem.6c03199.
    PubMed    
    Abstract available

  120. SINGH V, Aggarwal A, Akhtar MR, Pandey M, et al
    Comparison of quality of life and sexual function after ileal vs. sigmoid orthotopic neobladder reconstruction following nerves, vas deferens, and seminal vesicle-sparing radical cystectomy: A prospective randomized study.
    Urol Oncol. 2026;44:82-91.
    PubMed    
    Abstract available

  121. CAI LK, Yang X, Cao Q, Tian W, et al
    [MRI-based deep learning model for preoperative prediction of urothelial carcinoma with variant histology of bladder: a retrospective, multicenter study].
    Zhonghua Wai Ke Za Zhi. 2026;64:752-759.
    PubMed    
    Abstract available

  122. YAJIMA S, Imasato N, Hashimoto T, Kobayashi S, et al
    Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.
    Urol Oncol. 2026;44:13-24.
    PubMed    
    Abstract available

  123. GABRIEL PE, Seisen T, Xylinas E, Duquesne H, et al
    Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee.
    Ann Surg Oncol. 2026;33:7790-7800.
    PubMed    
    Abstract available

  124. YAPRAK BAYRAK B, Kosemehmetoglu K, Ozbek B, Simsek S, et al
    Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E-cadherin, P120, HER2 and TRPS1.
    Histopathology. 2026;89:338-346.
    PubMed    
    Abstract available

  125. YONESE I, Koga F, Toide M, Maezawa Y, et al
    Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).
    Jpn J Clin Oncol. 2026;56:885-893.
    PubMed    
    Abstract available

  126. LIN Y, Xiang N, Yang Y, Huang S, et al
    Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis.
    Cancer Med. 2026;15:e72025.
    PubMed    
    Abstract available

  127. ZHANG Z, Zhao Y, Li Z
    Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report.
    Medicine (Baltimore). 2026;105:e49724.
    PubMed    
    Abstract available

  128. GRIFFO A
    Nanosensor-integrated catheters for chemical mapping of bladder cancer biomarkers.
    Nat Biomed Eng. 2026;10:1274.
    PubMed    


  129. TSUJINO T, Yamazaki S, Sakamoto M, Yoshikawa Y, et al
    A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
    Signal Transduct Target Ther. 2026;11:299.
    PubMed    
    Abstract available

  130. YANG H, Zhou C, Zhou Z, Zhang F, et al
    Corrigendum to "YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer" [Int. Immunopharmacol. 184 (2026) 116911].
    Int Immunopharmacol. 2026 Jul 17:117122. doi: 10.1016/j.intimp.2026.117122.
    PubMed    


  131. MEHMUD I, Peng L, Zhang Y, Liang R, et al
    Localized In-Situ Nanomedicine Synthesis Enables Copper-Mediated Cuproptosis for Effective Bladder Cancer Therapy.
    Eur J Pharm Sci. 2026 Jul 17:107613. doi: 10.1016/j.ejps.2026.107613.
    PubMed    
    Abstract available

  132. BAO W, Liu Y, Yang J, Ma X, et al
    The diagnostic value of biparametric magnetic resonance imaging vesical imaging-reporting and data system combined with tumor contact length for assessing muscle invasion in bladder cancer lesions scored vesical imaging-reporting and data system 3: A
    Indian J Urol. 2026;42:225-231.
    PubMed    
    Abstract available

  133. AGRAWAL S, Pal AK, Sharma S, Tanwar R, et al
    The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials.
    Indian J Urol. 2026;42:254-255.
    PubMed    


  134. NAJMROCKA M, Semeniuk A, Stec R
    Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease - a case report.
    Front Oncol. 2026;16:1733345.
    PubMed    
    Abstract available

  135. ZHAO G, Bai Y, Chen X, Li J, et al
    Remodeling of the tumor microenvironment in muscle-invasive bladder cancer: insights from single-cell and spatial transcriptomics after neoadjuvant immunochemotherapy.
    Mol Cancer. 2026 Jul 17. doi: 10.1186/s12943-026-02738.
    PubMed    
    Abstract available

  136. PRIBUS SJ, Osredek I, Otonicar J, Simovic-Lorenz M, et al
    Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.
    Nat Commun. 2026;17:6384.
    PubMed    
    Abstract available

  137. MAHONEY ME, Jiang DM, Diaz-Mejia N, Atenafu EG, et al
    Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).
    Clin Genitourin Cancer. 2026;24:102599.
    PubMed    
    Abstract available

  138. FARIA EF, Rodrigues A, Pompeo A, Fazoli A, et al
    Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.
    Int Braz J Urol. 2026;52:e20260431.
    PubMed    
    Abstract available

  139. ASTUA IF, Suartz CV, Chade DC, Soares DFG, et al
    Bladder Cancer Management in Brazil's Supplementary Health System: Real-World Practice Patterns.
    Int Braz J Urol. 2026;52:e20260218.
    PubMed    
    Abstract available

  140. ZHANG Q, Xu K, Chen Z, Li Z, et al
    Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study.
    Front Oncol. 2026;16:1784832.
    PubMed    
    Abstract available

  141. CHEN H, Liu N, Chen X, Xian P, et al
    Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive invasive bladder cancer.
    Front Oncol. 2026;16:1880457.
    PubMed    
    Abstract available

  142. ATTYA ME, Sayed HY
    The clinicopathological significance of METTL3/SERPINE2 immunoexpression in urothelial carcinoma of the urinary bladder.
    Pol J Pathol. 2026;77:53-61.
    PubMed    
    Abstract available

  143. SUZUKI S, Cohen SM
    Effects of Nicotine on Urinary Bladder Carcinogenesis.
    Pathol Int. 2026;76:e70151.
    PubMed    
    Abstract available

  144. PATTOU M, Roupret M, Kamat A, Boorjian SA, et al
    Novel BCG Combination or Modified BCG Regimens in BCG-Naive High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2026 Jul 15:S2405-4569(26)00115.
    PubMed    
    Abstract available

  145. AI Z, Zhou H, Jiang L, Lang Y, et al
    YAP1 lactylation confers cisplatin resistance and prognostic value by suppressing ferroptosis via FOSL1 in bladder cancer.
    Cell Rep. 2026;45:117692.
    PubMed    
    Abstract available

  146. BAI Z, Wang S, Wang H, Liu Z, et al
    Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention.
    Int J Clin Oncol. 2026 Jul 15. doi: 10.1007/s10147-026-03139.
    PubMed    
    Abstract available

  147. PEIXOTO GA, Salles MP, Amaro Junior E, Korkes F, et al
    Rigid cystoscopy versus flexible outpatient cystoscopy: the economic cost behind the epidemiological and social impact.
    Einstein (Sao Paulo). 2026;24:eGS1136.
    PubMed    
    Abstract available

  148. GOTO T, Teramoto Y, Elahi Najafi MA, Yasui M, et al
    Role of Latrophilin-1 and Latrophilin-2 as Downstream Effectors of Androgen Receptor Signaling in Urothelial Tumorigenesis.
    Cancer Rep (Hoboken). 2026;9:e70624.
    PubMed    
    Abstract available

  149. GUGLIELMO P, Perrone E, Ozcan PP, Mapelli P, et al
    Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.
    Q J Nucl Med Mol Imaging. 2026;70:83-88.
    PubMed    
    Abstract available

  150. WANG Z, Zhou Z, Yang S, Zhao Z, et al
    Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
    Front Immunol. 2026;17:1777092.
    PubMed    
    Abstract available

  151. SUI J, Chen Y, Jiang Y, He Q, et al
    Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer.
    Cancer Manag Res. 2026;18:609903.
    PubMed    
    Abstract available

  152. OZTURK MI, Ekici M, Aydin C, Caglayan MS, et al
    Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies.
    J Clin Med. 2026;15:5199.
    PubMed    
    Abstract available

  153. CARRIERE PP, Hassanzadeh CJ
    Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
    J Clin Med. 2026;15:5101.
    PubMed    
    Abstract available

  154. BISSETTE RG, Congress Z, Nomdedeu-Sancho G, Wajih N, et al
    Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening.
    Int J Mol Sci. 2026;27:6082.
    PubMed    
    Abstract available

  155. JERSINOVIC S, Vukovic M, Hennenlotter J, Lutfrenk T, et al
    Nectin-4 Expression in Muscle-Invasive Bladder Cancer Is Associated with Growth-Related and Inflammatory Signaling Pathways.
    Int J Mol Sci. 2026;27:5706.
    PubMed    
    Abstract available

  156. CHEN Y, Cai L, Yang X, Tao Y, et al
    An Immunohistochemistry-Based Molecular Subtyping Approach for Capturing Clinical Outcome Heterogeneity in Bladder Cancer.
    Diagnostics (Basel). 2026;16:2055.
    PubMed    
    Abstract available

  157. SIM KC, Kim MJ, Sung DJ, Park BJ, et al
    Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.
    Diagnostics (Basel). 2026;16:1948.
    PubMed    
    Abstract available

  158. MORA-GARIJO B, Rahman S, Xu H, Chatzkel J, et al
    Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.
    Cancers (Basel). 2026;18:2174.
    PubMed    
    Abstract available

  159. PAN Q, Shi Q, Zhao Y, Yu T, et al
    MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer.
    Cancers (Basel). 2026;18:2164.
    PubMed    
    Abstract available

  160. YANG MH, Nagisetti Y, Mukundan A, Karmakar R, et al
    Early Classification of Bladder Cancer Using Spectrum-Aided Visual Enhancer (SAVE) and Deep Learning Models: A Non-Invasive Technology for Faster Detection.
    Cancers (Basel). 2026;18:2147.
    PubMed    
    Abstract available

  161. FIGOLS M, Gonzalez A, Fernandez-Saorin M, Bautista A, et al
    Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:2054.
    PubMed    
    Abstract available

  162. KWINTA L, Konopka K, Okon K, Lobacz M, et al
    Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.
    Cancers (Basel). 2026;18:2046.
    PubMed    
    Abstract available

  163. KAMI REDDY KR, Putluri V, Piyarathna DWB, Park JH, et al
    Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.
    Cell Commun Signal. 2026 Jul 14. doi: 10.1186/s12964-026-03058.
    PubMed    
    Abstract available

  164. MALIK M, Sigorski D, Jacyk P, Rozycki M, et al
    ddMVAC versus gemcitabine-cisplatin as neoadjuvant treatment for muscle-invasive urothelial bladder cancer: a multicenter real-world study.
    Sci Rep. 2026 Jul 14. doi: 10.1038/s41598-026-60676.
    PubMed    
    Abstract available

  165. MCGRATH J, Banerjee I, Ishiyama Y, Balaji KC, et al
    Network meta-analysis of immune checkpoint inhibitors in BCG-naive, high-risk non-muscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 14:S1078-1439(26)00565.
    PubMed    
    Abstract available

  166. WU K, Wang B, Chen Y, Zhou J, et al
    Corrigendum to "DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling" [Cellular Signaling, 2015 Sep 26; 27(12): 2515-2523].
    Cell Signal. 2026 Jul 14:112700. doi: 10.1016/j.cellsig.2026.112700.
    PubMed    


  167. YAJIMA S, Yoshida S, Imasato N, Chen W, et al
    Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis.
    Clin Genitourin Cancer. 2026;24:102603.
    PubMed    
    Abstract available

  168. KARABULUT B, Dag O, Kosemehmetoglu K, Guner G, et al
    Can We Foresee Grade and Stage Progression in Mixed Low- and High-Grade Noninvasive Papillary Urothelial Carcinomas?
    APMIS. 2026;134:e70238.
    PubMed    
    Abstract available

  169. UYSAL E, Yilmaz Y, Akin Y, Gorgel SN, et al
    Demographic and histopathological features of patients with primary bladder cancer without recurrence in two-year follow-up.
    J Pak Med Assoc. 2026;76:1026-1032.
    PubMed    
    Abstract available

  170. REN J, Lu J, Xiong Z, Zhang Y, et al
    Latent profile analysis of health-related quality of life in patients with bladder cancer and abdominal wall stomas: a multicenter cross-sectional study.
    BMC Urol. 2026 Jul 13. doi: 10.1186/s12894-026-02253.
    PubMed    
    Abstract available

  171. KONG J, Huang Y, Xing Y, Fang S, et al
    Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers.
    BMC Med Imaging. 2026;26:266.
    PubMed    
    Abstract available

  172. GUPTA N, Kumar M, Phulware RH
    Bladder carcinoma associated with anti-NXP2-positive inflammatory myopathy: a case-based review.
    Rheumatol Int. 2026;46:207.
    PubMed    
    Abstract available

  173. ZHUANG J, Yu H, Chen Y, Sun H, et al
    HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8(+) T cell infiltration and activation in bladder cancer.
    Cancer Lett. 2026;657:218729.
    PubMed    
    Abstract available

  174. HE X, Zhu H, Huang Y, Deng X, et al
    Analysis of the relationship between serum LAMC2, TROAP and clinical stages and prognosis of non-muscle invasive bladder cancer.
    Open Med (Wars). 2026;21:20261481.
    PubMed    
    Abstract available

  175. MAJUMDER A, Dwyer Orr L
    Racial and ethnic differences in bladder cancer diagnosis, treatment, and specialty care access among Medicare fee-for-service beneficiaries: a cross-sectional study.
    Front Oncol. 2026;16:1797699.
    PubMed    
    Abstract available

  176. ABUHASANEIN S
    Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.
    Front Oncol. 2026;16:1845015.
    PubMed    
    Abstract available

  177. YU D, Zhang Y, Tang J, Qing J, et al
    A machine learning-guided epithelial plasticity score refines prognostication and immune-context stratification in muscle-invasive bladder cancer.
    Discov Oncol. 2026 Jul 13. doi: 10.1007/s12672-026-05555.
    PubMed    
    Abstract available

  178. CHEN D, Zhang C, Xue S, Zeng Y, et al
    LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer.
    Adv Sci (Weinh). 2026 Jul 13:e76604. doi: 10.1002/advs.76604.
    PubMed    
    Abstract available

  179. MASTROIANNI R, Tuderti G, Anceschi U, Bove AM, et al
    Robotic intracorporeal modified Bordeaux versus Padua ileal bladder: head-to-head surgical technique, perioperative and functional outcomes.
    Minerva Urol Nephrol. 2026;78:430-437.
    PubMed    
    Abstract available

  180. LO RE M, Cadenar A, Pezzoli M, Mancon S, et al
    Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.
    Minerva Urol Nephrol. 2026;78:411-418.
    PubMed    
    Abstract available

  181. ZHU Q, Wang J, Wei Y, Liu W, et al
    Preliminary feasibility of SHURUI single-port robot-assisted radical cystectomy with exploratory comparison to a contemporaneous da Vinci Xi single-port cohort.
    Minerva Urol Nephrol. 2026;78:383-388.
    PubMed    
    Abstract available

  182. YALCIN B, Tuncay E, Arslan S, Araci HE, et al
    Survival in Synchronous Versus Metachronous Bladder and Prostate Cancer.
    Arch Esp Urol. 2026;79:800-807.
    PubMed    
    Abstract available

  183. PEREZ-BARTIVAS L, Leiva-Cepas F, Ponferrada D, Flores-Paco P, et al
    Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy.
    Arch Esp Urol. 2026;79:773-782.
    PubMed    
    Abstract available

  184. XU Y, Xu J, Han C, Li Q, et al
    Bioinformatics analysis of PFKFB family in pan-cancer and preliminary exploration of PFKFB4 in bladder cancer.
    Cancer Cell Int. 2026 Jul 13. doi: 10.1186/s12935-026-04354.
    PubMed    
    Abstract available

  185. WANG W, Dong F, Lei J, Li L, et al
    Soluplus(R)-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy.
    Int J Pharm. 2026;701:127190.
    PubMed    
    Abstract available

  186. ZSCHABITZ S, Bhatti I, Casuscelli J, Pachmayr LO, et al
    Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
    Cancer Immunol Immunother. 2026;75:184.
    PubMed    
    Abstract available

  187. CHEN DN, Wang JM, Zhang FH, Ye HY, et al
    KIF26B promotes bladder cancer progression through activating the NF-kappaB signaling pathway.
    iScience. 2026;29:116577.
    PubMed    
    Abstract available

  188. ZHANG X, Wang H, Zhou H, Xiao D, et al
    An AI-powered diagnostic system for grading and invasion of non-muscle-invasive bladder cancer via TURBT specimens: A multicenter study.
    iScience. 2026;29:116651.
    PubMed    
    Abstract available

  189. HAN C, Miao L, Liu Y, Wang Y, et al
    Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer.
    Transl Androl Urol. 2026;15:199.
    PubMed    
    Abstract available

  190. REN W, Yi J, Zeng M, Cheng H, et al
    The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer.
    Transl Androl Urol. 2026;15:201.
    PubMed    
    Abstract available

  191. ABOU CHAKRA M, Myers AA, Marchetti KA, Zakharia Y, et al
    Impact of age on the effectiveness of intravesical Bacillus Calmette?Guerin and gemcitabine/docetaxel in treatment-naive high-risk non?muscle?invasive bladder cancer.
    Transl Androl Urol. 2026;15:215.
    PubMed    
    Abstract available

  192. GABRIEL PE, Ingles JC, Zhu A, Horowitz A, et al
    Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.
    Transl Androl Urol. 2026;15:221.
    PubMed    
    Abstract available

  193. TANG S, Wang X, Chen F, Zhang L, et al
    Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.
    Transl Androl Urol. 2026;15:200.
    PubMed    
    Abstract available

  194. NIELSEN NK, Hjort PB, Hansen EB, Graugaard-Jensen C, et al
    Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.
    Eur Urol Open Sci. 2026;90:92-100.
    PubMed    
    Abstract available

  195. GU J, Wang M, Zhou Z, Zhang M, et al
    Associations between the intratumoral microbiome and the host transcriptome in bladder cancer and their implications for prognostic prediction.
    Sci Rep. 2026 Jul 11. doi: 10.1038/s41598-026-61819.
    PubMed    
    Abstract available

  196. YAJIMA S, Yoshida S, Imasato N, Chen W, et al
    Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026 Jul 11:S1078-1439(26)00566.
    PubMed    
    Abstract available

  197. YAO Y, Yang P, Niu S, Yang J, et al
    GLI2 confers ferroptosis resistance in bladder cancer by transcriptionally upregulating PRDX1.
    Apoptosis. 2026;31:191.
    PubMed    
    Abstract available

  198. SILVA A, Baltazar F, Afonso J
    Metabolic Reprogramming in the Bladder Cancer Microenvironment: Bridging Fundamental Research and Therapeutic Avenues for Cancer-Associated Fibroblasts.
    Adv Exp Med Biol. 2026;1501:145-164.
    PubMed    
    Abstract available

  199. MARTIN EW, Aragon-Ching JB
    Circulating tumor DNA (ctDNA)-guided adjuvant therapy for muscle-invasive bladder cancer (MIBC): ready for primetime?
    Ann Transl Med. 2026;14:42.
    PubMed    


  200. ABID S, Qasim N, Qaisar A, Nadeem A, et al
    FDA approval of mitomycin hydrogel (Zusduri): a new non-surgical era for non-muscle-invasive bladder cancer (NMIBC).
    Ann Med Surg (Lond). 2026;88:3930-3934.
    PubMed    
    Abstract available

  201. NIELSEN NK, Milling RV, Hjort PB, Vasquez JL, et al
    Histopathological Advantages of En Bloc Resection in Non-muscle-invasive Bladder Cancer: A Multinational Randomised Controlled Clinical Trial.
    Eur Urol Open Sci. 2026;90:69-76.
    PubMed    
    Abstract available

  202. KANG Y, Zhong G, Zhang Y, Chang Z, et al
    Exploring the response shift effects on patient-reported outcomes among postoperative bladder cancer patients: a qualitative study in China.
    BMC Urol. 2026 Jul 10. doi: 10.1186/s12894-026-02247.
    PubMed    
    Abstract available

  203. WANG H, Ji YA, Luo W, Xie Q, et al
    Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer.
    Sci Rep. 2026 Jul 15. doi: 10.1038/s41598-026-60910.
    PubMed    
    Abstract available

  204. GAUCHER C, Vicier C, Guerin M
    [Update: Evolution in the management of metastatic urothelial carcinomas].
    Bull Cancer. 2026;113.
    PubMed    
    Abstract available

  205. WANG G, Liu F, Chen Z, Davoli T, et al
    conMItion: an R package adjusting confounding factors for associations in multi-omics.
    Bioinformatics. 2026;42:btag472.
    PubMed    
    Abstract available

  206. WAFA H, van Creij NCH, Guenther M, Noeparast M, et al
    Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.
    Cancer Treat Rev. 2026;148:103173.
    PubMed    
    Abstract available

  207. LIN L, Li H, Zhou Q, Ding Q, et al
    Machine-intelligent multimodal algebot for intracavitary chemotherapy.
    Nat Nanotechnol. 2026;21:996-1007.
    PubMed    
    Abstract available

  208. GUO Q, Li L, Beeraka NM, Zhang Y, et al
    Sex-specific divergence in global urological cancer trajectories to 2050: A dual-model projection analysis based on GLOBOCAN and GBD databases.
    Eur J Surg Oncol. 2026;52:111943.
    PubMed    
    Abstract available

  209. CRUPI E, Cigliola A, Mercinelli C, Piacentini M, et al
    Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.
    Clin Genitourin Cancer. 2026;24:102583.
    PubMed    
    Abstract available

  210. SYNESI G, Lewis R, Kilburn L, Bliss J, et al
    Identifying underrepresented groups in oncology clinical trials using routinely collected data in an English academic trial setting.
    Trials. 2026;27:504.
    PubMed    
    Abstract available

  211. ELDESOUKI S, Elmekresh A, Esmaeilpour H, Kumar S, et al
    When double-J stents become a risk: bilateral distal ureteric urothelial carcinoma following ureteric instrumentation: a case report.
    BMC Urol. 2026;26:166.
    PubMed    
    Abstract available

  212. WANG G, Cheng Y, Zhou X, Guo Y, et al
    SEPT9 methylation as a potential biomarker for uncovering latent malignancy in flat urothelial lesions.
    Ann Diagn Pathol. 2026;84:152653.
    PubMed    
    Abstract available

  213. D'SOUZA AA, Groshen SG, Tsao-Wei D, Ruel N, et al
    Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.
    Curr Probl Cancer. 2026;63:101294.
    PubMed    
    Abstract available

  214. FUKUMORI Y, Nishimura K, Tohi Y, Osaki Y, et al
    Prostatic Abscess Secondary to Postoperative Wound Infection Caused by Mycobacterium mageritense.
    Intern Med. 2026;65:1985-1989.
    PubMed    
    Abstract available

  215. SASAKI Y, Endo Y, Ochiai T, Kin M, et al
    Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemical Carcinogen-induced Bladder Cancer.
    Anticancer Res. 2026;46:3651-3659.
    PubMed    
    Abstract available

  216. GHALI F, Tan WS
    A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 3. doi: 10.1111/bju.70377.
    PubMed    


  217. AYDOGDU C, Wang B, McSweeney ST, Diaz G, et al
    Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jul 2. doi: 10.1111/bju.70376.
    PubMed    
    Abstract available

  218. SOPUTRO NA, Wang L, Daher K, Al-Bayati A, et al
    Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.
    BJU Int. 2026;138 Suppl 1:S49-S55.
    PubMed    
    Abstract available

  219. DUAN Q
    Letter to the Editor regarding: reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Jul 17. doi: 10.1111/bju.70385.
    PubMed    


  220. SUN J, Jin K, Ding Y, Wu Y, et al
    Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.
    Cancer. 2026;132:e70515.
    PubMed    
    Abstract available

  221. LOTAN Y, Luu M, Liu M, Tikhonekov S, et al
    Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.
    Clin Cancer Res. 2026 Jul 2. doi: 10.1158/1078-0432.CCR-26-1407.
    PubMed    
    Abstract available

  222. LI Z, Izadmehr S, Hoffman-Censits J, Maughan B, et al
    Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
    Clin Cancer Res. 2026;32:2911-2920.
    PubMed    
    Abstract available

  223. CONTIERI R, van der Heijden AG, Mertens LS
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.
    Eur Urol. 2026 Jul 2:S0302-2838(26)02181-0. doi: 10.1016/j.eururo.2026.
    PubMed    


  224. MIAO J, Yi X
    Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org
    Eur Urol. 2026 Jul 9:S0302-2838(26)02241-4. doi: 10.1016/j.eururo.2026.
    PubMed    


  225. GONTERO P, Mariappan P, Pradere B, Rai BP, et al
    EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02111-1. doi: 10.1016/j.eururo.2026.
    PubMed    
    Abstract available

  226. KIKUCHI E, Kobayashi T, Shono M, Hoffman J, et al
    Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.
    Int J Urol. 2026;33:e70558.
    PubMed    
    Abstract available

  227. WANG Y, Zhao T, Liang B, Zhen L, et al
    Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer.
    Int Urol Nephrol. 2026 Jul 3. doi: 10.1007/s11255-026-05256.
    PubMed    
    Abstract available

  228. GAO M, Liu F, Wen J, Shen Y, et al
    Beyond VI-RADS: incremental value of quantitative mpMRI measurements for identifying muscle-invasive bladder cancer.
    Int Urol Nephrol. 2026 Jul 10. doi: 10.1007/s11255-026-05267.
    PubMed    
    Abstract available

  229. THIBAULT C, Bennamoun M, Flechon A, Gravis G, et al
    Neoadjuvant Durvalumab +/- Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
    J Clin Oncol. 2026;44:1921-1932.
    PubMed    
    Abstract available

  230. MARTIN A, Shi C, Martinez GM, Britton C, et al
    Long-term Outcomes of Partial Cystectomy for Urothelial Carcinoma in the Era of Bladder Preservation.
    Urology. 2026;213:131-140.
    PubMed    
    Abstract available

  231. KENNEDY-YOON D, Almohtasib J, Kaul S, Fleishman A, et al
    Association of Patient, Disease, and Socioeconomic Characteristics With Receipt of Intravesical Bacillus Calmette-Guerin Therapy From 2002-2017 and the Impact of BCG Supply Shortages.
    Urology. 2026;213:88-95.
    PubMed    
    Abstract available

  232. HAO X, Ye C, Lai W, Xu J, et al
    Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
    BMC Cancer. 2026;26:805.
    PubMed    
    Abstract available

  233. WANG Y, Ailiyaer A, Chen S, Wang W, et al
    Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
    BMC Cancer. 2026;26:813.
    PubMed    
    Abstract available

  234. MOHANTY P, Subhangini M
    Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum


;